A Study of the Influence of Central Obesity on the Esophageal Epithelial Barrier

Overview

About this study

This study is being done to help understand why some people with an increased amount of central obesity, without gastroesophageal reflux, develop changes to the lining of their esophagus that can potentially lead to esophageal adenocarcinoma (cancer).

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria

Is undergoing clinically indicated 24-hour ambulatory impedance pH monitoring (off reflux medications for 7 days) in the Esophageal Function Laboratory at Mayo Clinic, followed by endoscopy within 24-96 hours

Exclusion Criteria

Pre-existing or suspected Barrett's Esophagus (> 1cm of columnar mucosa in esophagus on endoscopy
Oral anticoagulation precluding endoscopic biopsies
Known hypersensitivity to fluorescein sodium
Nickel/metal allergies
Pacemaker
Scheduled for an MRI within 30 days after Bravo placement

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location	Status
Rochester, Minn. Mayo Clinic principal investigator Prasad Iyer, M.D.	Closed for enrollment

Mayo Clinic Location

Status

Rochester, Minn.

Mayo Clinic principal investigator

Prasad Iyer, M.D.

Closed for enrollment

More information

Publications

Publications are currently not available

Clinical Trials